Hepatitis B Virus Reactivation Potentiated by Biologics

被引：23
作者：
Ogawa, Eiichi [1 ]
Wei, Mike T. [2 ]
Nguyen, Mindie H. [2 ]
机构：
[1] Kyushu Univ Hosp, Dept Gen Internal Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan
[2] Stanford Univ, Med Ctr, Dept Med, Div Gastroenterol & Hepatol, 750 Welch Rd,Suite 210, Palo Alto, CA 94304 USA
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 02期
关键词：
Hepatitis B virus; Reactivation; Prophylaxis; Nucleos(t)ide analogue; CHEMOTHERAPY-INDUCED REACTIVATION; HBV REACTIVATION; C VIRUS; HEPATOCELLULAR-CARCINOMA; LAMIVUDINE THERAPY; ANTIVIRAL THERAPY; TARGETING BTK; T-CELLS; INFECTION; PATHOGENESIS;
D O I：
10.1016/j.idc.2020.02.009
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.
引用
收藏
页码：341 / +
页数：20
相关论文
共 87 条
  • [61] Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy Analysis of 257 Cases
    Perez-Alvarez, Roberto
    Diaz-Lagares, Candido
    Garcia-Hernandez, Francisco
    Lopez-Roses, Leopoldo
    Brito-Zeron, Pilar
    Perez-de-Lis, Marta
    Retamozo, Soledad
    Bove, Albert
    Bosch, Xavier
    Sanchez-Tapias, Jose-Maria
    Forns, Xavier
    Ramos-Casals, Manuel
    [J]. MEDICINE, 2011, 90 (06) : 359 - 371
  • [62] American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
    Perrillo, Robert P.
    Gish, Robert
    Falck-Ytter, Yngve T.
    [J]. GASTROENTEROLOGY, 2015, 148 (01) : 221 - U378
  • [63] Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease
    Perrillo, RP
    [J]. GASTROENTEROLOGY, 2001, 120 (04) : 1009 - 1022
  • [64] Puig Lluis, 2018, Curr Probl Dermatol, V53, P49, DOI 10.1159/000479475
  • [65] Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
    Razavi-Shearer, Devin
    Gamkrelidze, Ivane
    Nguyen, Mindie H.
    Chen, Ding-Shinn
    Van Damme, Pierre
    Abbas, Zaigham
    Abdulla, Maheeba
    Abou Rached, Antoine
    Adda, Danjuma
    Aho, Inka
    Akarca, Ulus
    Al Ali, Fuad Hasan
    Al Lawati, Faryal
    Al Naamani, Khalid
    Alashgar, Hamad Ibrahim
    Alavian, Seyed M.
    Alawadhi, Sameer
    Albillos, Agustin
    Al-Busafi, Said A.
    Aleman, Soo
    Alfaleh, Faleh Z.
    Aljumah, Abdulrahman A.
    Anand, Anil C.
    Nguyen Thu Anh
    Arends, Joop E.
    Arkkila, Perttu
    Athanasakis, Kostas
    Bane, Abate
    Ben-Ari, Ziv
    Berg, Thomas
    Bizri, Abdul R.
    Blach, Sarah
    Brandao Mello, Carlos E.
    Brandon, Samantha M.
    Bright, Bisi
    Bruggmann, Philip
    Brunetto, Maurizia
    Buti, Maria
    Chan, Henry L. Y.
    Chaudhry, Asad
    Chien, Rong-Nan
    Choi, Moon S.
    Christensen, Peer B.
    Chuang, Wan-Long
    Chulanov, Vladimir
    Clausen, Mette R.
    Colombo, Massimo
    Cornberg, Markus
    Cowie, Benjamin
    Craxi, Antonio
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 383 - 403
  • [66] Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
    Rehermann, Barbara
    [J]. NATURE MEDICINE, 2013, 19 (07) : 859 - 868
  • [67] Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013
    Schweitzer, Aparna
    Horn, Johannes
    Mikolajczyk, Rafael T.
    Krause, Gerard
    Ott, Joerdis J.
    [J]. LANCET, 2015, 386 (10003) : 1546 - 1555
  • [68] Hepatitis B virus biology
    Seeger, C
    Mason, WS
    [J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2000, 64 (01) : 51 - +
  • [69] Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
    Seggewiss, R
    Loré, K
    Greiner, E
    Magnusson, MK
    Price, DA
    Douek, DC
    Dunbar, CE
    Wiestner, A
    [J]. BLOOD, 2005, 105 (06) : 2473 - 2479
  • [70] Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
    Seto, Wai-Kay
    Chan, Thomas S. Y.
    Hwang, Yu-Yan
    Wong, Danny Ka-Ho
    Fung, James
    Liu, Kevin Sze-Hang
    Gill, Harinder
    Lam, Yuk-Fai
    Lie, Albert K. W.
    Lai, Ching-Lung
    Kwong, Yok-Lam
    Yuen, Man-Fung
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) : 3736 - +
123456789